About the Corrona Research Foundation (CRF)

The CRF, an independent, not for profit 501(c)3 foundation, was founded in early 2014 with the recognition that a mechanism was needed to connect talented academic epidemiology researchers in rheumatic diseases with the rich observational data collected by CorEvitas, LLC. The CRF will be able to access all of the data which has been collected since the inception of the registry. The Foundation will connect the data with qualified academic researchers for the purpose of producing scientific publications which improve our understanding of the effects of new and existing drug treatments. It is apparent that the CorEvitas data are a unique resource in the US as there are no other sources of prospectively collected physician and patient-derived, observational, uniform, deep data on a very large number of patients in the unique US marketplace. The CorEvitas data are collected at the time of a routine clinical encounter and are derived from patient and physician questionnaires completed at regular intervals. The data include standardized outcomes derived from a rheumatologist’s examination with recording of joint counts, visual analogue scales, standardized patient-reported outcomes, laboratory values, radiographic outcomes, bone densities, infections, comorbidities and side effects/toxicities from a very large cohort receiving a representative array of therapeutic interventions in this geographic space. As such, they are an unprecedented source of reliable, and representative, data on the many patients receiving these agents in the US marketplace.

Mission & Vision

Mission of the CRF
The CRF will improve patient care by providing qualified academic researchers access to the distinctive real world observational data which is collected on patients with RA, Spondyloarthropathies, and Psoriatic Arthritis. The epidemiological insights derived from these unique data sources will improve the quality of patient care by continuing to provide meaningful insights to their treating physicians on the many and varied outcomes of the drugs they use to treat these diseases. The CRF will facilitate and encourage connections with talented epidemiologic researchers across the medical disciplines of rheumatology.

Vision of the CRF
The CRF will expand the data capabilities of CorEvitas, LLC in order to become the source of real-world data on the many new agents used in the treatment of the inflammatory diseases treated by our very large group of physician participants.

Board of Directors

Joel M. Kremer, MD
President & Chairman of Board of Directors
Pffaf Family Professor of Medicine, Albany Medical College. Director of Research, The Center for Rheumatology. Founder, Corrona, LLC (now CorEvitas)
Stanley Cohen, MD
Clinical Professor of Internal Medicine, UTSouthwestern Medical School; Medical Director, Metroplex Clinical Research Center, Dallas, Texas. Director Rheumatology Division, Presbyterian Hospital, Dallas, Texas.
Daniel E. Furst, MD
Professor of Rheumatology, University of Florence, Italy. Clinical Professor of Rheumatology, University of Washington, Seattle, WA. Professor of Rheumatology (emeritus), University of California, Los Angeles, CA.
Jeffery Greenberg, MD, MPH
Clinical Associate Professor of Medicine, New York University School of Medicine. Chief Medical Officer, CorEvitas LLC.
Michael E. Weinblatt, MD
John R. and Eileen K. Riedman Professor of Medicine, Harvard Medical School. R. Bruce and Joan M. Mickey Distinguished Chair in Rheumatology Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital.
Jeff Curtis, MD, MS, MPH
Ed Keystone, MD
Leslie Harrold, MD, MPH
Chief Scientific Officer, CorEvitas, LLC.
Dimitrios Pappas, MD, MPH